{
    "clinical_study": {
        "@rank": "75668", 
        "arm_group": [
            {
                "arm_group_label": "Standard Manual Needle Injection", 
                "arm_group_type": "Active Comparator", 
                "description": "2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon"
            }, 
            {
                "arm_group_label": "Navigator Injection", 
                "arm_group_type": "Experimental", 
                "description": "2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this randomized, parallel-group, single-blinded, single center, Phase II\n      study is to collect data to compare the comfort and patient satisfaction of a hip injection\n      delivered via the Navigator compared to a standard needle injection.  In addition, delivery\n      preparation will be compared between a Navigator injection and a standard hip injection.\n      The data collected from this pilot study will serve as the basis to design a larger\n      multi-center study."
        }, 
        "brief_title": "Navigator vs Standard Needle Injection for Hip", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hip Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, \u226518 years of age, of any race or ethnicity;\n\n          -  Capable of completing self-administered questionnaires;\n\n          -  Patients with suspected intra-articular hip pain who have failed conservative care\n             (conservative care defined as a standard regimen of home or outpatient physical\n             therapy, activity modification, trial of at least one NSAID) for at least 3 months;\n\n          -  Candidate for a hip injection;\n\n          -  Have been informed of the nature of the study, agreeing to its requirements, and have\n             signed the informed consent approved by the Institutional Review Board/Ethics\n             Committee.\n\n          -  Subjects are able to understand and speak English\n\n        Exclusion Criteria:\n\n          -  History of intra-articular injection within the last 3 months  prior to the injection\n             procedure;\n\n          -  Complex regional pain syndrome;\n\n          -  History of prior hip surgery;\n\n          -  History of substance abuse;\n\n          -  Known history of hypersensitivity to local anesthetics of the amide type;\n\n          -  Contraindicated for Celestone (betamethasone sodium phosphate);\n\n          -  Contraindicated for Lidocaine Hydrochloride;\n\n          -  Is a prisoner or ward of the state;\n\n          -  Are unable to meet the treatment and follow up protocol requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066844", 
            "org_study_id": "PTC-0369"
        }, 
        "intervention": {
            "arm_group_label": [
                "Standard Manual Needle Injection", 
                "Navigator Injection"
            ], 
            "intervention_name": "2cc of Celestone and 5cc of Lidocaine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Betamethasone-17,21-dipropionate", 
                "Betamethasone", 
                "Betamethasone sodium phosphate", 
                "Lidocaine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hip Pain", 
            "Hip Injection", 
            "Hip Fracture", 
            "Hip Bursitis", 
            "Hip Arthritis", 
            "Hip Sciatica"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "last_name": "Kaili Pecorella", 
                "phone": "585-341-9305"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14642"
                }, 
                "name": "University of Rochester"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Navigator vs Standard Needle Injection for Hip", 
        "overall_official": {
            "affiliation": "University of Rochester", 
            "last_name": "Brian Giordano, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Injection Pain as measured by VAS for both treatment groups", 
            "safety_issue": "No", 
            "time_frame": "From 1 week to 12 weeks post-injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066844"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Global Patient Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "From 1 week to 12 weeks post-injection"
            }, 
            {
                "measure": "Drug Preparation Time", 
                "safety_issue": "No", 
                "time_frame": "From 1 week to 12 weeks post-injection"
            }, 
            {
                "measure": "Hip Pain and Function", 
                "safety_issue": "No", 
                "time_frame": "From 1 week to 12 weeks post-injection"
            }
        ], 
        "source": "Carticept Medical, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Carticept Medical, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}